Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes

Release Date: February 26, 2024
Expiration Date: February 26, 2025

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Program Overview:

The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, residual morbidity, and mortality remain, and additional strategies to slow kidney disease progression, particularly to address inflammation and fibrosis as a contributing factor to CKD progression, are needed. To that end, a novel non-steroidal MR antagonist (MRA) has been shown to decrease cardiorenal risk in patients with type 2 diabetes and chronic kidney disease. Even though this agent is now FDA-approved and is recommended by multiple guidelines, there is still a lack of familiarity among practicing clinicians about its role in the treatment of CKD in T2D, differences with steroidal MRAs, and its role with respect to SGLT-2is.

This interactive activity will walk you through a virtual “escape room game” format that is divided into two rooms, the first one being the “clinician's office,” where you will have a chance to review important information regarding the totality of the data with this novel approach and second is the “examination room” where you will apply your knowledge you gained in the first room to solve a case of a patient with T2DM and CKD, during this activity you can answer questions behind interactive 'hot spots’ and collect clues to 'escape' the room.

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
• Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
• Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs.
• Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based cardiologists, primary care physicians, endocrinologists, lipidologists as well as nurses, nurse practitioners, and pharmacists.

Christine Limonte, MD
Assistant Professor
Division of Nephrology
University of Washington
Seattle, Washington

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-24-015-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from February 26, 2024 through February 26, 2025.

1. Review the objectives and disclosures.
2. Study the educational content.
3. Successfully complete activity post-test(s).
4. Complete the activity evaluation.

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DISCLOSURES

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Limonte, faculty for this educational activity, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.